reason report
recap lower outlook set stage market growth
bottom line remain market perform view
compani still inadequ posit growth biolog
like lose share emerg standard biomolecular
analysi close tie competitor product
adopt new product includ bioaccord cyclic im
remain much longer term view share trade lower
anoth weak quarter driven declin industri appli food
etc market europ weak within ta divis lower-than-
expect growth china small molecul given on-going expans
rule recal deliv weak china org y/i declin
ta org y/i declin print well believ continu
lag behind peer market trend like bound
acceler still bright spot pharma growth
deliv y/i org growth believ larg come exist
instal base form servic contract recur consum
regul pharma set instrument growth step
quarter believ repres weaker recur revenu
sale longer term remain market perform reiter pt
continu priorit share repurchas aggress
invest growth attract acquisit spent
share repurchas quarter expect repurchas anoth
share vs pursu aggress invest growth
alloc capit toward attract acquisit could help expand
adjac market expect repurchas share
object increas leverag net-debt/ ebitda
believ new product introduct like take mani year
needl move adopt new product introduct includ
bioaccord cyclic im introduc asm like take
number year gain adopt biomolecular qa/qc lab
continu benefit q-tof synapt instrument given
market growth biomolecul also posit bioaccord
development stage biomolecul system ideal
regul qa/qc market howev qa/qc lab director gener
amen chang thu view bioaccord like take
year gain meaning traction spec bla nda
feedback cyclic im instrument remain mix respond
asm conf unclear applic instrument
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep present ex-amort one-tim charg
pleas refer page import disclosur price chart analyst certif
lower guid reflect uncertainti ahead lower
full year organ growth guid given uncertain
market condit weak europ china view new
product introduct gain traction market
modestli lower revenu estim prior
 ep move prior
reflect updat guidanc
rate water share market perform price target view
market perform given earlier sale forc realign continu impact lc-m
sale year believ steadi rise complex biomolecul bring
emerg standard includ mam multi attribut monitor alreadi becom
standard close attach orbitrap platform vs mass spec
pose threat uptak instrument longer term attempt address via
launch bioaccord system product still remain earli take multipl year
gain traction highli regul pharma qa/qc emerg standard rapidli gain
traction drug development head toward stronghold qa/qc despit
lc compani core custom expect mass spec util
ramp higher regul qa/qc industry-lead empow cd softwar
also like see increas competit see empow cd chrom data system
key recur instrument consum sale biopharma qa/qc
like face increas competit chromeleon agil open lab
come time key oper technic leadership transit mani
take retir believ face number headwind multipl front near
term longer term valuat reflect competit headwind compani
increasingli face view share buy-back market cap
strong continu provid support stock near-to-medium term
pt reflect ev/ebitda multipl discount
ev/ebitda lst multipl believ busi under-perform
peer group share current trade slightli tool averag believ
would warrant higher multipl sale rep reach full product help drive lc-
ms growth biopharma market still believ offer premium product
potenti return growth sale rep new mass spec product challeng launch
bioaccord address meet biotherapeut need market deriv price
target appli discount averag ev/ebitda multipl compris
primari risk price target includ
could acceler stock repurchas help drive stock higher one could also
envis biopharma uptick drive equival revenu growth across competitor
uptick biopharmaceut fund could pose risk know market remain
fda approv process directli impact biopharma biotech compani
could continu favor older method continu domin biopharma drug
sale could continu acceler result acceler spend current
level revenu deriv biopharma uptick spend
biopharma like increas revenu
acceler global budget research could caus upsid risk forecast expand
budget govern academ fund could result higher revenu rel
estim signific academ exposur revenu ww
nih exposur less revenu pickup academ spend could
headwind rate estim increas global budget could result shift
focu strategi growth could increas oper risk
emerg market pose signific upsid risk view despit signific growth
china far acceler uptak product could impact view sudden
macroeconom chang lead increas fund fund could impact water
posit china repres compani revenu chang regul
lead easier oper china foreign compani like benefit well given
posit market
high attach rate integr part busi model despit entri high
resolut mass spec lc could continu remain demand drive sale higher
estim could continu maintain legaci high attach rate lc
system due requir technolog competit chang market
fda regul remain paramount affect adopt rate clinic diagnost
tool clinic diagnost remain major growth area futur chang
regul restrict use mass spectromet clinic diagnost laboratori could
also improv compani prospect restrict could affect growth adopt rate certain
tool regul would also increas cost complianc test purpos
fx
buy-back
rest
good sold
interest expens incom
sg sale
 sale
oper expens sale
compani report svb leerink estim
